Showing results (91-100 of 227) with videos related to

Sort By:
Pageof 23
Cancer Cell|May 6, 2008
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growthSandra Ryeom, Kwan-Hyuck Baek, Matthew J Rioth, et al.
Cancer Research|June 19, 2007
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomasJohn M Pagel, Anastasia Pantelias, Nathan Hedin, et al.
Transplantation and Cellular Therapy|May 20, 2024
Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive ChemomobilizationAndrew J Portuguese, Albert C Yeh, Rahul Banerjee, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|November 28, 2017
Long-term results of a sirolimus-eluting stent with biodegradable polymer (RAPSTROM™) in de novo coronary stenosesFilippo Figini, Cholenahaly N Manjunath, Budanur C Srinivas, et al.
British Journal of Haematology|August 23, 2014
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patientsJohn M Pagel, Stephen E Spurgeon, John C Byrd, et al.
Transplantation and Cellular Therapy|April 25, 2021
Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective AnalysisAndrew J Cowan, Philip A Stevenson, Damian J Green, et al.
Blood|January 7, 2009
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsJohn M Pagel, Nural Orgun, Donald K Hamlin, et al.
Plos One|July 23, 2014
Nutrient addition dramatically accelerates microbial community successionJoseph E Knelman, Steven K Schmidt, Ryan C Lynch, et al.
Leukemia & Lymphoma|July 28, 2021
Idelalisib immune-related toxicity is associated with improved treatment responseNina D Wagner-Johnston, Jeff Sharman, Richard R Furman, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2020
KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell TransplantationAndrew J Cowan, Damian J Green, Mehdi Karami, et al.
Pageof 23